Analyst Ratings For Audentes Therapeutics Inc (NASDAQ:BOLD)
Today, HC Wainwright raised its price target on Audentes Therapeutics Inc (NASDAQ:BOLD) to $48.00 per share.
There are 10 Buy Ratings, 2 Sell Ratings, 2 Hold Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Audentes Therapeutics Inc (NASDAQ:BOLD) is Buy with a consensus target price of $39.0758 per share, a potential 2.92% downside.
Some recent analyst ratings include
- 4/26/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) gets downgraded to Sell by Citigroup
- 4/17/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Outperform rating reiterated by Leerink Swann with a $48.00 price target
- 2/27/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Hold rating reiterated by William Blair
- On 3/25/2019 Louis G Lange, Director, sold 20,000 with an average share price of $36.00 per share and the total transaction amounting to $720,000.00.
- On 2/25/2019 Matthew R Patterson, CEO, sold 21,000 with an average share price of $30.00 per share and the total transaction amounting to $630,000.00.
- On 2/25/2019 Suyash Prasad, VP, sold 10,000 with an average share price of $30.06 per share and the total transaction amounting to $300,600.00.
- On 12/24/2018 Louis G Lange, Director, sold 32,000 with an average share price of $18.62 per share and the total transaction amounting to $595,840.00.
- On 11/15/2018 Louis G Lange, Director, sold 24,000 with an average share price of $22.49 per share and the total transaction amounting to $539,760.00.
- On 10/1/2018 Matthew R Patterson, CEO, sold 21,000 with an average share price of $38.16 per share and the total transaction amounting to $801,360.00.
- On 10/1/2018 Suyash Prasad, VP, sold 10,000 with an average share price of $36.88 per share and the total transaction amounting to $368,800.00.
About Audentes Therapeutics Inc (NASDAQ:BOLD)
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Recent Trading Activity for Audentes Therapeutics Inc (NASDAQ:BOLD)
Shares of Audentes Therapeutics Inc closed the previous trading session at 40,25 −0,31 0,76 % with 39.65 shares trading hands.